Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06492512 · ClinicalTrials.gov registry record · Phase 4
Oral Iron Supplementation on Alternate Vs. Consecutive Days for Iron Deficiency Anemia in Pregnancy
A Phase 4 study of Pregnancy and Iron-deficiency Anemia (IDA), sponsored by Southern Illinois University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT06492512: Recruiting Phase 4 study of Pregnancy and Iron-deficiency Anemia (IDA), sponsored by Southern Illinois University.
NCT06492512 is a Phase 4 study of Pregnancy and Iron-deficiency Anemia (IDA) that is actively recruiting participants, run by Southern Illinois University. The registered enrollment target is 120 participants, below the 872-participant average among 191 other Pregnancy trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06492512, a Phase 4 study of Pregnancy and Iron-deficiency Anemia (IDA), is actively recruiting participants, sponsored by Southern Illinois University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
This will be a randomized clinical trial. Enrolled subjects will be randomized (1:1) into two study arms to receive either daily (Group 1) or alternate day (Group 2) supplementation with one oral pill containing ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill.
Primary Outcome
hemoglobin \> 10.5 g/dL
Conditions Studied
Interventions
- DRUG daily ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill
- DRUG alternate day ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill
Study Locations (1)
Illinois
- Southern Illinois University School of Medicine - Springfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-12 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 4 |
What NCT06492512 shows while recruiting
NCT06492512 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 872-participant average among 191 other Pregnancy trials with a reported enrollment target (86% lower).
The record links to 2 conditions, with Pregnancy appearing as the primary indexed condition, and to 2 interventions - of which daily ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill is the first listed.
NCT06492512 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06492512 about?
NCT06492512 is a clinical study titled "Oral Iron Supplementation on Alternate Vs. Consecutive Days for Iron Deficiency Anemia in Pregnancy". This will be a randomized clinical trial. Enrolled subjects will be randomized (1:1) into two study arms to receive either daily (Group 1) or alternate day (Group 2) supplementation with one oral pill containing ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill.
What is the current status of trial NCT06492512?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 2024-12. Estimated completion is 2028-06-30.
What conditions does trial NCT06492512 study?
This clinical trial studies the following conditions: Pregnancy, Iron-deficiency Anemia (IDA).
What interventions are being tested in trial NCT06492512?
The interventions under investigation include: daily ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill (DRUG), alternate day ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill (DRUG).
Who is sponsoring clinical trial NCT06492512?
This trial is sponsored by Southern Illinois University, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06492512 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pregnancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06492512's enrollment target sits among peer trials
120 111th of 191 higher than 81 of 191 other Pregnancy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pregnancy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effectiveness of Integrating Prenatal Care in Reducing HIV/STDs Among Young Pregnant Women
COMPLETED · Phase 4
-
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
RECRUITING
-
CGM Adherence Compared to Finger-stick Glucose Monitoring in Pregnancies With Type 2 Pregestational Diabetes
RECRUITING · NA
-
Healthy Start: Exploring the Fuel-mediated Programming of Neonatal Growth
RECRUITING
-
Cocooned Moms Study
RECRUITING · NA
-
Retinal Vascular Changes During Pregnancy
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia